US and European guidelines recommend intravenous albumin infusion combined with vasoconstrictors, such as terlipressin in HRS-AKI.3,4 However, limited studies exist on the prognostic implications of mortality in those with HRS versus non-HRS AKI, especially among patients with cirrhosis who require KRT. This evidence concerns the gene ALB and acute kidney injury.